Page last updated: 2024-08-16

zonisamide and oxidopamine

zonisamide has been researched along with oxidopamine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Gluck, MR; Granson, H; Santana, LA; Yahr, MD1
Asanuma, M; Diaz-Corrales, FJ; Kikkawa, Y; Kimoto, N; Miyazaki, I; Miyoshi, K; Murata, M; Takeshima, M1
Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y1
Nambu, A; Sano, H1
Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y1

Other Studies

5 other study(ies) available for zonisamide and oxidopamine

ArticleYear
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide

2004
Neuroprotective effects of zonisamide target astrocyte.
    Annals of neurology, 2010, Volume: 67, Issue:2

    Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Glutathione; Isoxazoles; Male; Mice; Mice, Inbred ICR; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkinson Disease; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tyrosine 3-Monooxygenase; Zonisamide

2010
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Biochemical and biophysical research communications, 2012, Nov-23, Volume: 428, Issue:3

    Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide

2012
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
    Neurochemistry international, 2019, Volume: 124

    Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide

2019
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
    Neuropharmacology, 2021, 10-15, Volume: 198

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide

2021